| 1 |
34741118 | Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models. | 2022 Mar |
1 |
| 2 |
34808021 | Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms. | 2022 Feb |
1 |
| 3 |
35020848 | The autoimmune encephalitis-related cytokine TSLP in the brain primes neuroinflammation by activating the JAK2-NLRP3 axis. | 2022 Jan 28 |
2 |
| 4 |
35169231 | Macrophage Jak2 deficiency accelerates atherosclerosis through defects in cholesterol efflux. | 2022 Feb 15 |
1 |
| 5 |
35278531 | Ruxolitinib ameliorates progressive anemia and improves survival during episodes of emergency granulopoiesis in Fanconi C-/- mice. | 2022 May |
2 |
| 6 |
35352806 | Epigenetic downregulation of Socs2 contributes to mutant N-Ras-mediated hematopoietic dysregulation. | 2022 May 1 |
2 |
| 7 |
33542546 | Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents. | 2021 Mar |
1 |
| 8 |
33567809 | Crucial role of hematopoietic JAK2 V617F in the development of aortic aneurysms. | 2021 Jul 1 |
1 |
| 9 |
33589712 | Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice. | 2021 Feb 15 |
1 |
| 10 |
34145036 | CDK6 Is a Therapeutic Target in Myelofibrosis. | 2021 Aug 15 |
1 |
| 11 |
34184542 | Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models. | 2021 Aug |
1 |
| 12 |
34196308 | Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy. | 2021 Jul 1 |
1 |
| 13 |
34367186 | Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition. | 2021 |
4 |
| 14 |
34440089 | Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway. | 2021 Jul 24 |
2 |
| 15 |
34480104 | Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy. | 2021 Oct |
2 |
| 16 |
31732720 | Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations. | 2020 Apr |
1 |
| 17 |
32562787 | Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease. | 2020 Aug |
1 |
| 18 |
32818511 | Ruxolitinib attenuates intimal hyperplasia via inhibiting JAK2/STAT3 signaling pathway activation induced by PDGF-BB in vascular smooth muscle cells. | 2020 Nov |
5 |
| 19 |
32929154 | Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis. | 2020 Oct |
1 |
| 20 |
30305729 | Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth. | 2019 Feb |
1 |
| 21 |
30959824 | Three Polymethoxyflavones Purified from Ougan (Citrus reticulata Cv. Suavissima) Inhibited LPS-Induced NO Elevation in the Neuroglia BV-2 Cell Line via the JAK2/STAT3 Pathway. | 2019 Apr 5 |
1 |
| 22 |
31195136 | IL-22 Accelerates Thymus Regeneration via Stat3/Mcl-1 and Decreases Chronic Graft-versus-Host Disease in Mice after Allotransplants. | 2019 Oct |
1 |
| 23 |
29515770 | Ruxolitinib significantly enhances in vitro apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model. | 2018 Feb 9 |
2 |
| 24 |
29643232 | Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. | 2018 Apr 11 |
1 |
| 25 |
29971909 | Captopril mitigates splenomegaly and myelofibrosis in the Gata1low murine model of myelofibrosis. | 2018 Sep |
1 |
| 26 |
30247637 | Janus kinase JAK1 maintains the ovarian reserve of primordial follicles in the mouse ovary. | 2018 Nov 1 |
1 |
| 27 |
28339658 | Acute cell volume regulation by Janus kinase 2-mediated sodium/hydrogen exchange activation develops at the late one-cell stage in mouse preimplantation embryos. | 2017 Mar 1 |
1 |
| 28 |
28687621 | Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. | 2017 Sep 15 |
1 |
| 29 |
28854975 | Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL. | 2017 Aug 30 |
2 |
| 30 |
29042365 | Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. | 2017 Dec 28 |
2 |
| 31 |
25721043 | Targeting BCR-ABL and JAK2 in Ph+ ALL. | 2015 Feb 26 |
1 |
| 32 |
25977345 | Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects. | 2015 Aug 15 |
2 |
| 33 |
26446793 | Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities. | 2015 Nov 27 |
1 |
| 34 |
24957147 | JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. | 2014 Aug 28 |
4 |
| 35 |
25289677 | Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. | 2014 |
5 |
| 36 |
25549138 | A method for screening and validation of resistant mutations against kinase inhibitors. | 2014 Dec 7 |
1 |
| 37 |
22875628 | Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements. | 2013 Mar |
1 |
| 38 |
24251790 | Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. | 2013 Nov |
2 |
| 39 |
21926964 | Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. | 2012 Apr |
2 |